.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,798,091

« Back to Dashboard
Patent 5,798,091 protects IMAGENT and is included in one NDA.

This patent has thirty-two patent family members in eighteen countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 5,798,091

Title: Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
Abstract:A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.
Inventor(s): Trevino; Leo A. (San Diego, CA), Schutt; Ernest George (San Diego, CA), Klein; David H. (Carlsbad, CA), Tarara; Thomas E. (San Diego, CA), Weers; Jeffry G. (San Diego, CA), Kabalnov; Alexey (San Diego, CA)
Assignee: Alliance Pharmaceutical Corp. (San Diego, CA)
Application Number:08/395,680
Patent Claim Types:
see list of patent claims
Use; Compound; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 2002DISCNNo5,798,091► subscribe METHOD OF USE OF IMAGENT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 5,798,091

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
5,798,091 August 25, 2010

Non-Orange Book Patents for Patent: 5,798,091

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,720,938 Systems for the formation of microbubbles► subscribe
5,605,673 Stabilized microbubble compositions for ultrasound► subscribe
7,141,235Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,798,091

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria281183► subscribe
Australia4922196► subscribe
Australia5199701► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc